Frontlight ResearchEarly access
TerminatedPhase 2
AK104 for Recurrent or Metastatic Vulvar Cancer
Key facts
- Who runs it
- Akeso
- Where
- China6 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 20 people enrolled
- Started
- 25 Aug 2023
- Ended
- 31 May 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- AK104
- AK104+ Paclitaxel+Cisplatin or Carboplatin
- Record updated
- 28 September 2026
- Why it stopped
- Sponsor decision
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Age >=18 and <=80. ECOG of 0 or 2. Life expectancy ≥ 3 months. Histologically confirmed vulvar cancer (squamous cell carcinoma or adenosquamous carcinoma), not amenable to curative surgery or radical radiotherapy
- For Cohort A, subjects should have experienced failure on at least one previous systemic therapy, or intolerance to standard therapy
- At least one measurable tumor lesion per RECIST v1.1. Adequate organ function as assessed in the laboratory tests. Female subjects of childbearing potential must have a negative serum pregnancy test prior to the the first administration and agree to use effective methods of contraception
Who cannot take part
- Systemic or curative (surgery or radiotherapy) anti-tumor therapy within 4 weeks prior to the first administration
- Previous treatment with immune checkpoint inhibitors (e.g., anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, etc.)
- Subjects with other histopathological types of vulvar cancer, such as melanoma, sarcoma, etc
- Active or potentially recurrent autoimmune disease
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, open-label, phase II clinical study, aiming to the evaluate the efficacy and safety of AK104 (an anti- PD-1 and CTLA-4 bispecific antibody), alone or combined with chemotherapy, in subjects with recurrent or metastatic vulvar cancer not amenable to curative surgery or radiotherapy.
The 2 groups in the trial
- Cohort A: AK104Treatment being tested
AK104 monotherapy
Treatment: AK104
- Cohort B: AK104+chemotherapyTreatment being tested
AK104 combined with platinum-based chemotherapy (paclitaxel+ cisplatin or carboplatin)
Treatment: AK104+ Paclitaxel+Cisplatin or Carboplatin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Open-label, Phase II Study of AK104 in the Treatment of Recurrent or Metastatic Vulvar Cancer
- Record updated
- 28 September 2026